Successfully overcoming the substantial and broad challenges presented by cancer will rely heavily on synergies among a variety of disciplines and areas of expertise. We are committed to funding dynamic teams of investigators who are pooling their capabilities, knowledge, and energies to transform how cancer is prevented, diagnosed, and treated.
Below are the centers that have been created with our funding:
Members of MFICM are working to change cancer treatment paradigms using cutting-edge analytics to maximize the use of diverse, high-content data sets. They are using advances in machine learning to capture, integrate, and derive insights from clinical data, genomics, liquid biopsies (detecting tumor DNA in the blood), molecular/digital imaging, and 3D tumor mapping collated from hundreds of patients in real time and uncover insights that will ultimately help physicians more accurately select effective therapies for their patients and more rapidly determine whether treatments are working or not.
The Mark Foundation Center at Penn brings together leading cancer researchers using state-of-the-art molecular, cellular, and radiologic technologies to better understand and optimally modulate immune signaling pathways activated in patients treated with radiation therapy. Scientists on the team are using this knowledge to identify optimal combinations of radiotherapy and other cancer treatments such as immunotherapies and CAR T cells.
Members of the Mark Foundation Center at Johns Hopkins are bringing together the tools of astronomy image analysis, pathology, computer science, cancer genomics, and immunogenomics to solve problems in oncology. Researchers on the team are seeking innovative solutions to expand the number of cancer patients who benefit from immunotherapy through the identification of new biomarkers and insights into immune system responses.
The Mark Foundation is supporting a new phase of discovery for a team of investigators previously funded as the Stand Up to Cancer Lung Dream Team. Members of this multi-institutional team are collaborating to develop, optimize, and integrate translational studies of targeted therapies and immunotherapies to improve outcomes for patients with the most common and hardest to treat lung cancers.